Table 2.
Time to benefit for LDL-C lowering strategies
| Non-statins | Control | Trial | Time to benefit |
|---|---|---|---|
| Cholestyramine | placebo | LRC-CPPT57 | 7.4 years |
| partial ileal bypass surgery | no surgery | POSCH58 | 9.7 years |
| Ezetimibe with simvastatin 40 mg | placebo with simvastatin 40 mg | IMPROVE-IT56 | 7.0 years |
| Statins | |||
| Rosuvastatin | placebo | JUPITER12 | 1.9 years |
| Pravastatin | placebo | WOSCOPS8 | 5.0 years |
| placebo | CARE6 | 5.0 years | |
| placebo | LIPID17 | 6.1 years | |
| Atorvastatin | placebo | SPARCL184 | 4.9 years |
| placebo | ASCOT-LLA11 | 3.3 years | |
| Lovastatin | placebo | AFCAPS/Tex-CAPS9 | 5.2 years |
| Simvastatin | placebo | HPS10 | 2.0 years |
| placebo | 4S5 | 5.4 years | |
| Fluvastatin | placebo | LIPS16 | 3.9 years |